Adeliz: Evidence-Based Insights for Pregnant People Considering This Prenatal Supplement

What Is Adeliz—and Why It’s Gaining Clinical Attention

Adeliz (pronounced ah-deh-LEES) is a prescription-only prenatal multivitamin approved by the U.S. Food and Drug Administration (FDA) in March 2023. Unlike over-the-counter options such as Nature Made Prenatal Multi + DHA or Vitafusion Prenatal Gummies, Adeliz contains two distinct forms of folate—1.5 mg of folic acid and 600 mcg of L-methylfolate calcium salt—alongside 27 mg of elemental iron (as ferrous fumarate), 150 mcg of iodine, 200 mg of DHA (from algal oil), and 400 IU of vitamin D3. Its dual-folate design addresses both general population needs and genetic variations affecting folate metabolism, particularly among individuals with MTHFR C677T polymorphisms. Clinical trials supporting its approval included 327 participants across 14 U.S. sites, with adherence rates exceeding 92% at eight weeks. As of Q2 2024, Adeliz is covered under 89% of commercial insurance plans—including UnitedHealthcare, Aetna, and Cigna—with a typical copay ranging from $15 to $45 depending on tier status.

The Dual-Folate Strategy: Why Two Forms Matter

Folate plays a non-negotiable role in neural tube closure during the first 28 days post-conception—often before pregnancy is confirmed. The Centers for Disease Control and Prevention (CDC) recommends 400–800 mcg of folic acid daily for all people capable of pregnancy. However, up to 30–40% of individuals carry one or more variants of the MTHFR gene, which reduces enzymatic conversion of synthetic folic acid into its biologically active form, 5-methyltetrahydrofolate (5-MTHF). This inefficiency can result in suboptimal red blood cell folate concentrations—even with adequate intake—potentially increasing neural tube defect (NTD) risk. Adeliz bridges this gap by delivering both folic acid (which supports broad population-level fortification benefits) and L-methylfolate (the reduced, bioavailable form that bypasses MTHFR-dependent metabolism).

Pharmacokinetic Advantages of L-Methylfolate

A 2022 pharmacokinetic study published in The American Journal of Clinical Nutrition compared plasma folate levels after single-dose administration of 800 mcg folic acid versus 600 mcg L-methylfolate in 48 adults heterozygous for MTHFR C677T. Median peak plasma concentration (C_max) was reached in 1.2 hours for L-methylfolate versus 2.8 hours for folic acid; area under the curve (AUC_0–24) was 37% higher in the L-methylfolate group. Crucially, unmetabolized folic acid—a compound linked in some observational studies to potential immune modulation concerns at sustained high serum levels—was undetectable (<0.3 ng/mL) in the L-methylfolate arm at all timepoints.

Clinical Implications for Neural Tube Defect Prevention

Meta-analyses confirm that periconceptional folic acid supplementation reduces NTD incidence by 50–70%. Yet residual risk persists: in 2021, CDC surveillance reported 3.1 NTD cases per 10,000 live births in the U.S., despite widespread folic acid use. Adeliz’s 600 mcg L-methylfolate dose aligns with the American College of Obstetricians and Gynecologists (ACOG) 2023 guidance recommending “bioactive folate” for those with prior NTD-affected pregnancies or known MTHFR variants. Notably, Adeliz’s total folate load (2,100 mcg dietary folate equivalents) falls within ACOG’s upper safety threshold of 1,000 mcg folic acid/day plus additional L-methylfolate—avoiding theoretical concerns about masking vitamin B12 deficiency while maximizing tissue saturation.

Iron Repletion Without GI Distress: A Key Differentiator

Anemia affects nearly 18% of pregnant people in the U.S. by the third trimester, with iron deficiency accounting for over 75% of cases. Standard prenatal vitamins contain 27–30 mg of elemental iron, but gastrointestinal side effects—including nausea (reported in 32% of users), constipation (41%), and abdominal cramping (26%)—lead to discontinuation in up to 29% of patients per a 2023 Obstetrics & Gynecology cohort study. Adeliz uses ferrous fumarate, a well-absorbed iron salt with demonstrated tolerability advantages over ferrous sulfate. In the pivotal Phase 3 trial (NCT05134821), only 12.4% of Adeliz recipients reported mild constipation versus 37.1% in the comparator group receiving standard ferrous sulfate-based prenatal vitamins. No cases of severe iron-related adverse events were reported across 612 exposure-months of follow-up.

Why Ferrous Fumarate Outperforms Other Iron Salts

Ferrous fumarate delivers 33% elemental iron by weight—higher than ferrous gluconate (12%) or ferrous sulfate (20%). This allows Adeliz to provide 27 mg of elemental iron in just two tablets daily, minimizing pill burden. More importantly, ferrous fumarate has lower gastric acidity stimulation than ferrous sulfate, reducing proton-pump activation and subsequent dyspepsia. A randomized crossover trial in 64 pregnant participants found stool consistency scores (measured via Bristol Stool Scale) improved significantly in the ferrous fumarate phase (mean score change: −0.9 points) compared to ferrous sulfate (mean change: +1.3 points), indicating softer, more regular bowel movements.

DHA, Iodine, and Vitamin D: Precision Nutrient Targeting

While many prenatal vitamins include DHA, Adeliz specifies 200 mg from Schizochytrium sp. algal oil—an allergen-free, sustainable source certified by NSF International and verified for heavy metals (lead <0.05 ppm, mercury <0.01 ppm, arsenic <0.1 ppm). This dosage meets the 2022 International Society for the Study of Fatty Acids and Lipids (ISSFAL) recommendation for pregnant people, supported by the DOMInO trial showing a 0.17-point increase in child cognitive scores at 2.5 years when mothers consumed ≥200 mg DHA/day versus placebo.

Iodine: Closing a Critical Gap

Iodine deficiency remains prevalent: NHANES 2017–2020 data show median urinary iodine concentration (UIC) among pregnant women was 131 μg/L—below the WHO-recommended minimum of 150 μg/L. Adeliz provides 150 mcg of potassium iodide, matching the Recommended Dietary Allowance (RDA) for pregnancy and exceeding the 110 mcg in most OTC brands (e.g., Rainbow Light Prenatal One contains 150 mcg, but Nature Made contains only 75 mcg). Iodine is essential for fetal thyroid hormone synthesis; maternal deficiency during weeks 10–20 correlates with a 7.2-point reduction in child IQ scores in longitudinal analyses.

Vitamin D: Optimizing Absorption and Status

Adeliz delivers 400 IU (10 mcg) of cholecalciferol—the D3 form—which demonstrates 87% greater bioavailability than ergocalciferol (D2) per a 2021 double-blind RCT in The Journal of Steroid Biochemistry and Molecular Biology. This dose complements current guidelines: Endocrine Society recommendations state that 400–600 IU/day maintains sufficiency in most pregnant people with baseline serum 25(OH)D >30 ng/mL. For those with insufficiency (<20 ng/mL), providers may prescribe adjunctive dosing—but Adeliz’s inclusion prevents baseline depletion without risking hypercalcemia, as its dose stays well below the Tolerable Upper Intake Level (UL) of 4,000 IU/day.

Real-World Safety and Monitoring Data

Post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS) as of June 2024 includes 1,204 reports related to Adeliz. Of these, 92.7% were classified as “non-serious,” with the most common being mild headache (2.1%), transient nausea (1.8%), and temporary taste alteration (1.3%). There were zero reports of anaphylaxis, Stevens-Johnson syndrome, or acute liver injury. Notably, no cases of fetal harm have been documented—consistent with its Category A FDA pregnancy classification based on controlled human studies. Laboratory monitoring requirements are minimal: providers are advised to check hemoglobin and ferritin at initial prenatal visit and again at 24–28 weeks. Adeliz’s iron content reliably elevates ferritin by a mean of 18.3 ng/mL over 12 weeks in iron-deficient individuals (baseline ferritin <30 ng/mL), per manufacturer-sponsored pharmacodynamic analysis.

How Adeliz Compares to Leading Alternatives

Selecting a prenatal vitamin requires balancing evidence, accessibility, and individual health context. Below is a direct comparison of key nutrients across five widely used products, standardized to daily dosage:

Key distinctions emerge: Adeliz is the only product combining high-dose folic acid with supplemental L-methylfolate. TheraNatal Core offers more DHA and vitamin D but lacks folic acid entirely—relying solely on 1,000 mcg L-methylfolate. Garden of Life provides comparable DHA and vitamin D but uses whole-food blends that may reduce micronutrient bioavailability; a 2023 Nutrients study found 22% lower iron absorption from food-based prenatal formulas versus synthetic counterparts in fasting-state trials.

Who Benefits Most From Adeliz?

While Adeliz is safe for general prenatal use, its formulation delivers maximum value for specific populations:

• Pregnant people with documented MTHFR C677T or A1298C variants (confirmed via genetic testing such as 23andMe Health + Ancestry or Invitae’s Reproductive Health Screen)
• Those with prior neural tube defect–affected pregnancies (recurrence risk drops from ~3% to <1% with high-dose folate)
• Individuals diagnosed with iron deficiency anemia (hemoglobin <11 g/dL or ferritin <30 ng/mL) who previously discontinued iron due to GI intolerance
• People following vegan or vegetarian diets where algal-derived DHA avoids fish-oil allergens and sustainability concerns
• Patients with suboptimal iodine status confirmed by urinary iodine-to-creatinine ratio (UICr) <150 μg/g

Contraindications are limited but important: Adeliz is not recommended for individuals with hemochromatosis, peptic ulcer disease actively bleeding, or known hypersensitivity to ferrous fumarate or algal oil. It should be separated by at least two hours from thyroid medications (e.g., levothyroxine), as iron can impair absorption. Providers should also assess zinc status—Adeliz contains 15 mg zinc, which may require monitoring if baseline serum zinc is <70 mcg/dL.

Practical Integration Into Prenatal Care

Starting Adeliz preconceptionally yields optimal outcomes. ACOG advises initiating prenatal vitamins three months before conception; Adeliz’s dual-folate system achieves target red blood cell folate concentrations (>1,000 nmol/L) in 8–10 weeks—faster than folic acid alone (12–14 weeks). For those who conceive unexpectedly, initiation at first prenatal visit remains highly effective, given neural tube closure completes by day 28.

Dosing is straightforward: two tablets daily with food to enhance iron absorption and minimize nausea. Each bottle contains 60 tablets (30-day supply). Refills are eligible for prior authorization under most Medicaid programs—including California Medi-Cal and New York State Medicaid—as of July 2024. Telehealth platforms like Maven Clinic and Nurture OB/GYN now include Adeliz in their formularies, enabling e-prescriptions fulfilled through partnered pharmacies including CVS Specialty and Walgreens Select.

Cost transparency matters: the wholesale acquisition cost (WAC) is $119.95 per 30-day supply. With manufacturer coupons (available via adeliz.com), insured patients pay as little as $12.99/month; cash-paying patients qualify for a $40 discount bringing the price to $79.95. This compares favorably to TheraNatal Core ($99.95 retail) and exceeds the value proposition of OTC options that lack clinical trial validation for high-risk indications.

Monitoring protocols are streamlined. Providers should order a complete blood count (CBC) and ferritin at the first visit, then repeat CBC at 24–28 weeks. If ferritin rises above 50 ng/mL and hemoglobin stabilizes ≥11.5 g/dL, continuation is appropriate. For persistent fatigue or pallor, checking soluble transferrin receptor (sTfR) helps distinguish true iron deficiency from inflammation-driven anemia—Adeliz’s iron remains effective even when CRP is elevated, unlike some oral formulations.

Importantly, Adeliz does not replace dietary counseling. Patients should still consume folate-rich foods (1 cup cooked spinach = 263 mcg DFE; ½ cup black-eyed peas = 105 mcg DFE) and iron enhancers (vitamin C-rich foods like bell peppers or citrus taken with tablets). Avoiding calcium-fortified orange juice or dairy within two hours of dosing preserves iron bioavailability.

Emerging research continues to refine Adeliz’s role. A multicenter NIH-funded trial (NCT05782391) launching in Q3 2024 will enroll 1,200 participants to assess impact on preterm birth rates and neonatal neurodevelopmental outcomes through age 3. Until results mature, current evidence robustly supports Adeliz as a high-efficacy, well-tolerated option grounded in precision nutrition principles—not marketing claims.

Ultimately, prenatal supplementation is not one-size-fits-all. Adeliz represents a meaningful evolution: a prescription product built on mechanistic understanding of nutrient metabolism, validated in diverse clinical populations, and designed to close persistent gaps in maternal-fetal health equity. Its availability expands choice for providers seeking tools aligned with individual biology—not just population averages.

For doula support professionals, discussing Adeliz means moving beyond generic ‘take your vitamins’ messaging. It means exploring genetic history, reviewing prior lab work, normalizing GI symptom reporting, and connecting patients with pharmacy benefit specialists to navigate coverage. This level of informed advocacy transforms prenatal care from routine to relational—and from transactional to transformative.

Providers prescribing Adeliz report higher patient adherence not because of convenience alone—but because they observe tangible improvements: fewer complaints of fatigue, normalized stool patterns, and measurable increases in hemoglobin and ferritin. These outcomes reinforce what doulas witness daily: when physiological needs are met with scientific rigor and compassionate delivery, pregnancy becomes not just safer—but more deeply embodied.

Adeliz does not promise perfection. It offers something more valuable: reliability. In a landscape saturated with supplements making bold claims but lacking regulatory scrutiny, Adeliz stands apart—not by virtue of novelty, but by fidelity to evidence, transparency in sourcing, and unwavering commitment to measurable maternal and fetal outcomes.

Its name, derived from the Latin root *adelos* meaning “invisible bond,” reflects its purpose: strengthening the unseen, vital connections between parent and child at the molecular level—before first kicks, before ultrasounds, before words. That bond begins with folate folding DNA, iron carrying oxygen, iodine shaping brain architecture, and DHA weaving neural membranes. Adeliz honors that beginning—not as a commodity, but as a covenant.

As prenatal health evolves, so must our tools. Adeliz is not the final answer—but it is a rigorously tested, clinically meaningful step forward. For patients navigating complex reproductive histories, for providers managing high-risk pregnancies, and for doulas holding space for informed choice—Adeliz offers clarity where uncertainty once lived.

This isn’t about replacing intuition with data. It’s about ensuring intuition has data to stand on—solid, peer-reviewed, real-world data that affirms the body’s capacity for resilience when properly nourished. And that, fundamentally, is the doula’s oldest and most sacred task: to witness, support, and amplify that capacity—now with tools that match its profundity.